Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$8.63

-0.18 (-2.04%)

16:58
02/07/18
02/07
16:58
02/07/18
16:58

Gemphire Therapeutics files to sell common stock, no amount given

Piper Jaffray & Co. is acting as the lead book-running manager for the offering. Raymond James & Associates, Inc. is also acting as a book-runner for the offering.

GEMP Gemphire Therapeutics
$8.63

-0.18 (-2.04%)

01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
12/22/17
ROTH
12/22/17
NO CHANGE
Target $30
ROTH
Buy
Gemphire transition to NASH a value creator, says Roth Capital
Roth Capital analyst Yasmeen Rahimi views Gemphire Therapeutics' transition into non-alcoholic steatohepatitis as an "important shareholder value creator." After the company announced the launch of proof-of-concept Phase 2a trial of gemacabene in eight patients with familial partial lipodystrophy, a rare genetic metabolic condition characterized by abnormal distribution of subcutaneous fat which then leads to NASH, the analyst keeps a Buy rating on Gemphire with a $30 price target.
10/19/17
ROTH
10/19/17
INITIATION
Target $30
ROTH
Buy
Gemphire Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Gemphire Therapeutics with a Buy rating and $30 price target driven by her confidence in the clinical success of the company's one and only candidate for the treatment of dyslipidemia and fatty liver disease.
09/20/17
ADAM
09/20/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire data support commercial viability of gemcabene, says Canaccord
After Gemphire Therapeutics reported that a combined data analysis showed a 21% LDL-C reduction for 600mg gemcabene, Canaccord analyst John Newman said he thinks the data support a clinically meaningful and commercially viable drug. The analyst, who expects gemcabene to continue to show a very clean safety profile and is interested to see if cardiovascular benefit will be part of the efficacy assessment of a Phase 3 trial, keeps a Buy rating and $31 price target on Gemphire shares.

TODAY'S FREE FLY STORIES

HPP

Hudson Pacific

$30.66

0.42 (1.39%)

05:41
02/23/18
02/23
05:41
02/23/18
05:41
Upgrade
Hudson Pacific rating change  »

Hudson Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

05:40
02/23/18
02/23
05:40
02/23/18
05:40
Downgrade
Rosneft rating change  »

Rosneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$37.41

-26.21 (-41.20%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Macquarie Infrastructure rating change  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Acacia Communications rating change  »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 13

    Mar

  • 29

    Mar

XPO

XPO Logistics

$93.56

-0.43 (-0.46%)

05:37
02/23/18
02/23
05:37
02/23/18
05:37
Recommendations
XPO Logistics analyst commentary  »

XPO free cash flow growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$39.85

0.34 (0.86%)

, BIVV

Bioverativ

$104.30

0.39 (0.38%)

05:35
02/23/18
02/23
05:35
02/23/18
05:35
Hot Stocks
Sanofi announces expiration of HSR waiting period for acquisition of Bioverativ »

Sanofi (SNY) announced…

SNY

Sanofi

$39.85

0.34 (0.86%)

BIVV

Bioverativ

$104.30

0.39 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

KNX

Knight-Swift

$47.83

-0.47 (-0.97%)

05:34
02/23/18
02/23
05:34
02/23/18
05:34
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGL

Sibanye Gold

$4.05

-0.38 (-8.58%)

05:26
02/23/18
02/23
05:26
02/23/18
05:26
Upgrade
Sibanye Gold rating change  »

Sibanye Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGIF

Ingenico Group

05:23
02/23/18
02/23
05:23
02/23/18
05:23
Downgrade
Ingenico Group rating change  »

Ingenico Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$30.53

-1.44 (-4.50%)

05:22
02/23/18
02/23
05:22
02/23/18
05:22
Hot Stocks
Momo acquires Tantan in cash, stock transaction »

Momo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$55.43

-0.27 (-0.48%)

05:20
02/23/18
02/23
05:20
02/23/18
05:20
Recommendations
GoDaddy analyst commentary  »

GoDaddy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Mar

SRE

Sempra Energy

$106.64

1.21 (1.15%)

05:19
02/23/18
02/23
05:19
02/23/18
05:19
Hot Stocks
Sempra Energy raises annualized dividend by 9% to $3.58 per share »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

MB

Mindbody

$35.55

2.2 (6.60%)

05:18
02/23/18
02/23
05:18
02/23/18
05:18
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

05:17
02/23/18
02/23
05:17
02/23/18
05:17
Upgrade
Financial Engines rating change  »

Financial Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$35.82

0.49 (1.39%)

05:14
02/23/18
02/23
05:14
02/23/18
05:14
Initiation
Okta initiated  »

Okta initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 07

    Mar

COTV

Cotiviti Holdings

$34.21

-0.32 (-0.93%)

05:11
02/23/18
02/23
05:11
02/23/18
05:11
Downgrade
Cotiviti Holdings rating change  »

Cotiviti downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARD

Ardagh Group

$19.01

0.8 (4.39%)

05:09
02/23/18
02/23
05:09
02/23/18
05:09
Recommendations
Ardagh Group analyst commentary  »

Ardagh should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$26.48

-0.29 (-1.08%)

05:03
02/23/18
02/23
05:03
02/23/18
05:03
Initiation
Boston Scientific initiated  »

Boston Scientific assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

SGMO

Sangamo

$25.40

3.2 (14.41%)

, GILD

Gilead

$79.40

-1.29 (-1.60%)

05:00
02/23/18
02/23
05:00
02/23/18
05:00
Recommendations
Sangamo, Gilead analyst commentary  »

Sangamo price target…

SGMO

Sangamo

$25.40

3.2 (14.41%)

GILD

Gilead

$79.40

-1.29 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$101.51

0.42 (0.42%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Eastman Chemical management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

Week of 2/23 Baker-Hughes…

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

San Francisco Federal…

UMICY

Umicore

$14.37

-0.185 (-1.27%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Umicore management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GVA

Granite Construction

$60.58

1.04 (1.75%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Granite Construction management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    May

LYG

Lloyds Banking

$3.92

-0.03 (-0.76%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Lloyds Banking management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.